home / stock / l / l news


L News and Press, Loews Corporation From 02/08/21

Stock Information

Company Name: Loews Corporation
Stock Symbol: L
Market: NYSE
Website: loews.com

Menu

L L Quote L Short L News L Articles L Message Board
Get L Alerts

News, Short Squeeze, Breakout and More Instantly...

L - Loews Q4 earnings saved by CNA Financial's strength

Loews (L) Q4 net income jumps 83% Y/Y, driven by its CNA Financial (CNA) unit, which logged in strong property and casualty underwriting results, solid net investment income, and net investment gains.Not surprisingly, Loews Hotels & Co. posted a net loss for the quarter as the COVID-19 pa...

L - Loews reports Q4 results

Loews (L): Q4 GAAP EPS of $1.45.Revenue of $3.71B (-4.1% Y/Y)Press Release For further details see: Loews reports Q4 results

L - Loews Corporation Reports Net Income Of $397 Million For The Fourth Quarter Of 2020

Loews Corporation Reports Net Income Of $397 Million For The Fourth Quarter Of 2020 22 Million Common Shares Repurchased In 2020 For $917 Million PR Newswire NEW YORK , Feb. 8, 2021 /PRNewswire/ -- Loews Corporation (NYSE: L) today reported net income of...

L - Loews Corporation to Release Fourth Quarter 2020 Results on February 8, 2021

Loews Corporation to Release Fourth Quarter 2020 Results on February 8, 2021 PR Newswire NEW YORK , Jan. 26, 2021 /PRNewswire/ -- Loews Corporation (NYSE: L) will report fourth quarter 2020 financial results on Monday, February 8, 2021 . The conference ...

L - Checkpoint Therapeutics initiated at Cantor with Overweight

Checkpoint Therapeutics ([[CKPT]] +8.2%) was initiated at Cantor Fitzgerald with an Overweight rating, PT $16.Analyst Jennifer Kim believes that the potential peak sales opportunity for cosibelimab is underappreciated.Quick look at pipeline:Analyst believes upwards earnings estimate revisions...

L - Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors

Jounce Therapeutics (JNCE) has initiated patient enrollment in INNATE Phase 1 clinical study of its lead macrophage program JTX-8064 as a monotherapy and in combination with either JTX-4014, its internal PD-1 inhibitor, or pembrolizumab in patients with advanced solid tumors.“Expansion...

L - Exicure's cavrotolimod Fast Track'd in U.S. for skin cancer

The FDA has granted Fast Track designations Exicure (XCUR) for its clinical product candidate, cavrotolimod (AST-008), for two development programs:Cavrotolimod in combination with anti-programmed death-1 (PD-1) therapy for the treatment of patients with locally advanced or metastatic Merkel ...

L - What Are the Key IRS Tax Changes for 2021?

Everyone's hoping that 2021 will be a lot different from how 2020 was. But when it comes to your 2021 income taxes, the IRS isn't planning on a huge transformation like we saw back in 2018 . Even without major tax reform, however, you still have to go through the minor changes that ...

L - Top Net Payout Yields - December 2020

The top net payout yield stocks far outperformed the total return of the S&P 500 during the period since the last report back in September. The top net payout yield stocks averaged 13.7% yields to start September. Biogen claimed the top spot with a yield of 22.7% to start Dece...

L - Loews Corporation: A 30% Discount On A Valuable Conglomerate

Loews Corporation is a little-discussed conglomerate with a valuable distribution of assets. Based on a simple sum-of-the-parts valuation, and not counting a recovery, the company trades at a 30% discount. We recommend taking the opportunity to invest in the company, and are expec...

Previous 10 Next 10